Ocular hypotensive DP-class prostaglandin receptor affinities determined by quantitative autoradiography on human eye sections

Journal of Ocular Pharmacology and Therapeutics

Volumn 21, Issue 2, 2005, Pages 121-132

  Sharif, Najam A ^a   Davis, Terry L ^a   Williams, Gary W ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13,14 DIHYDRO 9 CHLORO 15 CYCLOHEXYL 11,15 DIHYDROXY 3 OXO 16,17,18,19,20 PENTANOR 5,13 PROSTADIENOIC ACID; 13,14 DIHYDRO 9 CHLORO 15 CYCLOHEXYL 11,15 DIHYDROXY 3 OXO 16,17,18,19,20 PENTANOR 5,13 PROSTADIENOIC ISOPROPYL ESTER; 3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; 7 [3 (3 CYCLOHEXYL 3 HYDROXY 1 PROPENYL) 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 9BETA CHLORO 15 CYCLOHEXYL 9 DEOXY 16,17,18,19,20 PENTANOR 3 OXAPROSTAGLANDIN F2 ALPHA; AL 6556; AL 6598; PROSTAGLANDIN DP RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RADIOLIGAND; SQ 27986; TRITIUM; UNCLASSIFIED DRUG;

AQUEOUS HUMOR FORMATION; ARTICLE; AUTORADIOGRAPHY; CELL CULTURE; CHOROID; CILIARY BODY EPITHELIUM; CILIARY MUSCLE; CORNEA; DRUG RECEPTOR BINDING; FROZEN SECTION; HUMAN; HUMAN TISSUE; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; IRIS; LENS; RECEPTOR AFFINITY; RECEPTOR DENSITY; RETINA;

AGED; AGED, 80 AND OVER; AUTORADIOGRAPHY; BINDING, COMPETITIVE; EYE; FEMALE; HUMANS; MALE; OCULAR HYPOTENSION; PROSTAGLANDINS, SYNTHETIC; RADIOLIGAND ASSAY; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

EID: 17744389984     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2005.21.121     Document Type: Article

References (49)

1. Coleman, R.A., Humphrey, P.P.A., Kennedy, I., et al. Prostanoid receptors-the development of a working classification. Trends Pharmacol. Sci. 5:303-306, 1984.
2. Narumiya, S., Hirata, M., Namba, T., et al. Structure and function of prostanoid receptors. J. Lipid Mediat. 6:155-161, 1993.
3. 2α. Arch Ophthalmol., 105:1112-1116, 1987.
4. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res., 49:389-402, 1989.
5. 2α in the human eye. Graefe's Arch. Clin. Exp. Ophthalmol. 222: 139-141, 1985.
6. Sakurai, M., Araie, M., Oshika, T., et al. Effects of topical application of UF-021, a novel prostaglandin-related compound, on aqueous humor dynamics in rabbit. Jpn. J. Ophthalmol. 37:252-258, 1993.
7. 2α-1-isopropylester in the cynomolgus monkey. Exp. Eye Res. 48:707-716, 1989.
8. Bito, L.Z. Prostaglandins: A new approach to glaucoma management with a new intriguing side-effect. Surv. Ophthalmol. 41(Suppl 22):S1-S14, 1997.
9. Alm, A. Prostaglandin derivates as ocular hypertensive agents. Prog. Ret. Eye Res. 17:291-312, 1998.
10. 47(Suppl 1):S13-S33, 2002.
11. Woodward, D.F., Krauss, A.H.P, Chen, J., et al. The pharmacology of bimatoprost (Lumigan™). Surv. Ophthalmol., 45:(Suppl):S337-S45, 2001.
12. Camras, C.B., and Aim, A. Initial clinical studies with prostaglandins and their analogues. Surv. Ophthalmol., 41(Suppl 2):S61-S68, 1997.
13. 2 reduces intraocular pressure. Br. J. Ophthalmol. 72:461-464, 1988.
14. 2 and its analog, BW245C, on intraocular pressure in humans. Graefes' Arch. Clin. Exp. Ophthalmol. 229:411-415, 1991.
15. 2 receptor stimulation elicits ocular hypotensive effects in rabbits and cats. Eur. J. Pharmacol. 275:245-250, 1995.
16. 2α binding sites in the bovine iris ciliary body. Invest. Ophthalmol. Vis. Sci. 34:2237-2245, 1993.
17. Bhattacherjee, P., and Paterson, C.A. Studies on prostanoid receptors in ocular tissues. J. Ocul. Pharmaco. Ther. 10:167-175, 1994.
18. Sharif, NA. Quantitative autoradiographic methods. In Toga, A.W., and Mazziota, J.C., eds., Brain Mapping: The Methods, New York: Academic Press, 1996:115-144.
19. Sharif, N.A., and Eglen, R.M. Quantitative autoradiography: A tool to visualize and quantify receptors, enzymes, transporters, and second messenger systems. In Sharif, NA., ed., Molecular Imaging in Neuroscience. Oxford, UK: Oxford University Press, 1993:71-138.
20. Sharif, NA., and Hughes, J. Discrete mapping of brain mu and delta opioid receptors using selective peptides: Quantitative autoradiography, species differences, and comparison with kappa receptors. Peptides 10:499-522, 1989.
21. 2) receptor subtypes after chronic manipulation of dietary salt. Neurochem. Res. 20:121-128, 1995.
22. 3H] 9-β-(+) fluprostenol): Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J. Pharm. Pharmacol. 51: 685-694, 1999.
23. Davis, T.L., and Sharif, NA. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J. Ocul. Pharmacol. Ther. 15:323-336, 1999.
24. Sharif, N.A., Xu, S.X., Crider, J.Y., et al. Levobetaxolol (Betaxon™) and other β-adrenergic antagonists: Preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J. Ocul. Pharmacol. Ther. 17:305-317, 2001.
25. 2 receptor subtypes in porcine ocular tissues. I. Uveal tissues. J. Ocul. Pharmacol. Ther. 11:421-135, 1995.
26. 2α receptor messenger RNA and protein in the cynomolgus monkey eye. Invest. Ophthalmol Vis. Sci. 37:716-726, 1996.
27. 4, and FP receptors in human ciliary epithelial and ciliary muscle cells. Biochem. Pharmacol. 53:1249-1255, 1997.
28. 2 receptor is the predominant prostanoid receptor in the human ciliary muscle. Br. J. Ophthalmol. 77:110-114, 1993.
29. 3 and FP receptor binding sites in bovine corpus luteum: Characterization and correlation with functional data. J. Pharmacol. Expt. Ther. 286:1094-1102, 1998.
30. Coleman, R.A., Smith, W.L., Narumiya, S. VIII. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 46:205-229, 1994.
31. 2 in anesthetized guinea-pigs: Effect of DP-antagonist BWA868C. Br. J. Pharmacol. 100:761-767, 1990.
32. 2. Prostaglandins 35:277-300, 1988.
33. Giles, H., Leff, P., Bolof, M.L., et al. The classification of prostaglandin DP-receptors in platelets and vasculature using BWA868C, a novel, selective, and potent competitive antagonist. Br. J. Pharmacol. 96:291-300, 1989.
34. 3H]-BWA868C, a DP receptor-selective antagonist radioligand. Br. J. Pharmacol., 106:996-1003, 1992.
35. 2 receptor. J. Clin. Invest., 64:586-590, 1979.
36. Sharif, N.A., Crider, J.Y., Xu, S.X., et al. Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: Focus on DP class prostanoids. J. Pharmacol. Exp. Ther. 293:321-328, 2000.
37. McPherson, G.A. Analysis of radioligand binding experiments on a microcomputing system. Trends Pharmacol. Sci., 4:369-370, 1983.
38. 2 analogs on adenylate cyclase in rabbit iris-ciliary body membrane fractions. Exp. Eye Res. 51:585-590, 1990.
39. Wiederholt, M. Direct involvement of trabecular meshwork in the regulation of aqueous humor outflow. Curr. Opin. Ophthalmol. 9:46-49, 1998.
40. Cazevielle, C., Muller, A., Meyner, F., et al. Protection by prostaglandins from glutamate toxicity in cortical neurons. Neurochem Int. 24:395-398, 1994.
41. Boie, Y., Sawyer, N., Slipetz, D.M., et al. Molecular cloning and characterization of the human prostanoid DP receptor. J. Biol. Chem. 270:18910-18916, 1995.
42. Gerashchenko, D., Beuckmann, C., Kanaoka, Y., et al. Dominant expression of rat prostanoid DP-receptor mRNA in leptomeninges, inner segments of photoreceptor cells, iris epithelium, and ciliary processes. J. Neurochem. 71:937-945, 1998.
43. Kyveris, A., Maruscak, E., and Senchyna, M. Optimization of RNA isolation from human ocular tissue and analysis of prostanoid receptor mRNA expression using RT-PCR. Mol Vis. 8:51-58, 2003.
44. Crider, J.Y, Griffin, B.W. and Sharif, N.A. Prostaglandin DP-receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: Pharmacological characterization using agonists and antagonists. Br. J. Pharmacol. 127:204-210, 1999.
45. Seiler, S., Brassard, C.L., and Federici, M.E. SQ-27986 inhibition of platelet aggregation is mediated through activation of platelet prostaglandin D2 receptors. Prostaglandins, 40:119-130, 1990.
46. 2-receptor. Prostaglandins, 35:855-868, 1988.
47. Schlotzer-Screhardt, U., Zenkel, M., and Nusing, M. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest. Ophthalmol. Vis. Res. 43:1475-1487, 2002.
48. Woodward, D.F., Spada, C.S., Hawley, S.B., et al. Further studies on ocular responses to DP-receptor stimulation. Eur. J. Pharmacol. 230:327-333, 1993.
49. Crawford, K.S., Kaufman, P.L., Hubbard, W.C., et al. The DP-receptor agonist SQ27986 raises but does not lower intraocular pressure in ocular normotensive monkeys. J. Glauc. 1:94-99, 1992.